Sign In
LGVN.US

Longeveron Inc. (LGVN) $1.4 IPO Settlement

Claim deadline for this case already passed by, but we can still try and file for compensation for you
S.D. Florida
Court
21-CV-23303
Case number
12 Feb 2021
Class period Start
12 Aug 2021
Class period End
08 Sept 2023
Claim deadline
Longeveron Inc. (LGVN) settles $1.3975 M with Investors.

The Complaint alleges that the Offering Documents were negligently prepared and, as a result, contained untrue statements of a material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Specifically, the Complaint alleges that the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that:
  1. Lomecel-B was not as effective in treating aging frailty as Defendants had led investors to believe;
  2. accordingly, Lomecel-B's clinical and commercial prospects with respect to aging frailty were overstated; and
  3. as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state the information required to be stated therein.
Alleged Offence
Misleading Statements
Failure to Disclose
Negligence
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
1.48
Filing date
13 September 2021
Plaintiffs
Jerald Vargas Malespin
Attorneys
The Rosen Law Firm, P.A. (New York, NY)
Defendants
Geoff Green, James Clavijo, Joshua M. Hare, Donald M. Soffer, Neil E. Hare, Rock Soffer
Judge
Hon. Roy K. Altman
Administrator
Strategic Claims Services
Court hearing date
10 October 2023
Exclusion deadline
25 August 2023
Objection deadline
26 September 2023
Hearing deadline
26 September 2023
Trades matching type
FIFO
+$1,397,500
Total Settlement Amount
Created by Stan Vick, Scout

Longeveron LLC

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigati...

    Ticker
    LGVN.US
    ISIN
    US54303L1044
    CIK
    1721484
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    Life Science and Technology Park, Miami, FL, United States, 33136